Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
BMC Psychiatry ; 23(1): 444, 2023 06 16.
Artículo en Inglés | MEDLINE | ID: mdl-37328751

RESUMEN

BACKGROUND: Psychosis treatment guidelines recommend cognitive behaviour therapy (CBT) and family intervention (FI), for all patients with first episode psychosis (FEP), though guidance borrows heavily from literature in adults from high income countries. To our knowledge, there are few randomized controlled trials (RCTs) examining the comparative effect of these commonly endorsed psychosocial interventions in individuals with early psychosis from high-income countries and no such trials from low and middle-income countries (LMICs). The present study aims to confirm the clinical-efficacy and cost-effectiveness of delivering culturally adapted CBT (CaCBT) and culturally adapted FI (CulFI) to individuals with FEP in Pakistan. METHOD: A multi-centre, three-arm RCT of CaCBT, CulFI, and treatment as usual (TAU) for individuals with FEP (n = 390), recruited from major centres across Pakistan. Reducing overall symptoms of FEP will be the primary outcome. Additional aims will include improving patient and carer outcomes and estimating the economic impact of delivering culturally appropriate psychosocial interventions in low-resource settings. This trial will assess the clinical-efficacy and cost-effectiveness of CaCBT and CulFI compared with TAU in improving patient (positive and negative symptoms of psychosis, general psychopathology, depressive symptoms, quality of life, cognition, general functioning, and insight) and carer related outcomes (carer experience, wellbeing, illness attitudes and symptoms of depression and anxiety). CONCLUSIONS: A successful trial may inform the rapid scale up of these interventions not only in Pakistan but other low-resource settings, to improve clinical outcomes, social and occupational functioning, and quality of life in South Asian and other minority groups with FEP. TRIAL REGISTRATION: NCT05814913.


Asunto(s)
Terapia Cognitivo-Conductual , Trastornos Psicóticos , Adulto , Humanos , Intervención Psicosocial , Trastornos Psicóticos/terapia , Terapia Cognitivo-Conductual/métodos , Resultado del Tratamiento , Ansiedad , Ensayos Clínicos Controlados Aleatorios como Asunto
3.
Transl Psychiatry ; 10(1): 415, 2020 11 30.
Artículo en Inglés | MEDLINE | ID: mdl-33257661

RESUMEN

NMDA autoantibody encephalitis presenting as schizophrenia suggests the possible role of adaptive cell-mediated immunity in idiopathic schizophrenia. However, to our knowledge there have been no trials of the immune-suppressant methotrexate in schizophrenia. We tested if low-dose methotrexate as used in the treatment of systemic autoimmune disorders would be tolerable and effective in people with schizophrenia in a feasibility study. Ninety-two participants within 5 years of schizophrenia diagnosis were recruited from inpatient and outpatient facilities in Karachi, Pakistan. They were randomised to receive once weekly 10-mg oral methotrexate (n = 45) or matching placebo (n = 47) both with daily 5-mg folic acid, in addition to treatment as usual for 12 weeks. There were eight dropouts per group. Side effects were non-significantly more common in those on methotrexate and were not severe. One person developed leukopenia. Positive symptom scores improved more in those receiving methotrexate than placebo (ß = -2.5; [95% CI -4.7 to -0.4]), whereas negative symptoms were unaffected by treatment (ß = -0.39; [95% CI -2.01 to 1.23]). There were no immune biomarkers but methotrexate did not affect group mean leucocyte counts or C-reactive protein. We conclude that further studies are feasible but should be focussed on subgroups identified by advances in neuroimmune profiling. Methotrexate is thought to work in autoimmune disorders by resetting systemic regulatory T-cell control of immune signalling; we show that a similar action in the CNS would account for otherwise puzzling features of the immuno-pathogenesis of schizophrenia.


Asunto(s)
Trastornos Psicóticos , Esquizofrenia , Humanos , Inmunosupresores , Metotrexato/uso terapéutico , Trastornos Psicóticos/tratamiento farmacológico , Esquizofrenia/tratamiento farmacológico
4.
Artículo en Inglés | MEDLINE | ID: mdl-23082573

RESUMEN

Smoking is a major public problem concern the world over. It is one of the major preventable causes of premature death and disease in the world. Fourteen to seventeen year olds are among a vulnerable group of individuals in society and susceptible to cigarette smoking. Older students act as role models to younger pupils and could influence smoking behavior. In a cross-sectional study we compared the differences in smoking between high school students in Pakistan and the United Kingdom. A self-administered anonymous questionnaire, adapted from a WHO questionnaire about tobacco smoking, was distributed to the students. In the UK, 235 participants were recruited; 16% (n = 38) were regular smokers. In Pakistan, 350 participants were recruited; 17% (n = 58) were regular smokers. In both countries males were significantly more likely to smoke. Reasons for smoking varied between the UK and Pakistan. In the UK, the majority smoked for recreational or social purposes and in Pakistan peer pressure played the major role. Beliefs regarding smoking were similar between the two countries. The lifetime prevalence of smoking was higher in the UK, but more students in Pakistan smoked daily. There were important differences in the smoking patterns between the two countries, which have potential public health implications.


Asunto(s)
Conducta del Adolescente , Fumar/epidemiología , Adolescente , Distribución de Chi-Cuadrado , Estudios Transversales , Femenino , Humanos , Masculino , Pakistán/epidemiología , Grupo Paritario , Prevalencia , Factores de Riesgo , Factores Sexuales , Encuestas y Cuestionarios , Reino Unido/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA